Sildenafil Citrate-Restored eNOS and PDE5 Regulation in Sickle Cell Mouse Penis Prevents Priapism Via Control of Oxidative/Nitrosative Stress

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Bivalacqua, Trinity J ^a   Musicki, Biljana ^a   Hsu, Lewis L ^b,c   Berkowitz, Dan E ^a   Champion, Hunter C ^d   Burnett, Arthur L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; REACTIVE OXYGEN METABOLITE; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PLEIOTROPY; PRIAPISM; PROTEIN PROTEIN INTERACTION; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION;

ANEMIA, SICKLE CELL; ANIMALS; BLOTTING, WESTERN; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITROSATION; OXIDATIVE STRESS; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PRIAPISM; PURINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SULFONES;

MUS;

EID: 84879741132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068028     Document Type: Article

References (33)

1. Broderick GA, (2012) Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med 9: 88-103.
2. Burnett AL, (2006) The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens (Greenwich) 8: 53-62.
3. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE, (2002) Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl 23: 92-97.
4. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL, (2005) Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 102: 1661-1666.
5. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL, (2007) Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 51: 1732-1740.
6. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, et al. (2009) Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med 6: 2494-2504.
7. Claudino MA, Franco-Penteado CF, Corat MA, Gimenes AP, Passos LA, et al. (2009) Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. J Sex Med 6: 2187-2196.
8. Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, et al. (2010) Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice. Urology 76: 510.e7-12.
9. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, et al. (2008) Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118: 1491-1501.
10. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, et al. (2010) Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med 7: 3011-3022.
11. Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, et al. (2009) The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol 297: C916-C927.
12. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B, (2006) Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 67: 1043-1048.
13. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B, (2006) Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 3: 1077-1084.
14. Paszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, et al. (1997) Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278: 876-878.
15. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, et al. (2009) Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 181: 899-906.
16. Takimoto E, Champion HC, Li M, Belardi D, Ren S, et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222.
17. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, et al. (2007) Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109: 3088-3098.
18. Musicki B, Champion HC, Hsu LL, Bivalacqua TJ, Burnett AL, (2011) Post-translational inactivation of endothelial nitric oxide synthase in the transgenic sickle cell mouse penis. J Sex Med 8: 419-426.
19. Munarriz R, Park K, Huang YH, Saenz de Tejada I, Moreland RB, et al. (2003) Reperfusion of ischemic corporal tissue: physiologic and biochemical changes in an animal model of ischemic priapism. Urology 62: 760-764.
20. Hotston M, Jeremy JY, Bloor J, Greaves NS, Persad R, et al. (2008) Homocysteine and copper interact to promote type 5 phosphodiesterase expression in rabbit cavernosal smooth muscle cells. Asian J Androl 10: 905-913.
21. Hemnes AR, Zaiman A, Champion HC, (2008) PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 294: L24-L33.
22. Kietadisorn R, Juni RP, Moens AL, (2012) Tackling endothelial dysfunction by modulating NOS-uncoupling: new insights in pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 302: E481-E495.
23. Wood KC, Hebbel RP, Lefer DJ, Granger DN, (2006) Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic Biol Med 40: 1443-1453.
24. Kanika ND, Melman A, Davies KP, (2010) Experimental priapism is associated with increased oxidative stress and activation of protein degradation pathways in corporal tissue. Int J Impot Res 22: 363-373.
25. Musicki B, Liu T, Sezen SF, Burnett A, (2012) Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penis. J Sex Med 9: 1980-1987.
26. Fosterman U, Sessa WC, (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33: 829-837.
27. Yamagishi S, Matsui T, (2011) Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharmacol Res 64: 187-194.
28. Lin G, Xin ZC, Lue TF, Lin CS, (2003) Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol 170(2 Pt 2): S15-S18.
29. Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, et al. (2006) Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 3: 419-431.
30. Behr-Roussel D, Oudot A, Caisey S, Coz OL, Gorny D, et al. (2008) Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur Urol 53: 1272-1280.
31. Schafer A, Fraccarollo D, Pförtsch S, Flierl U, Vogt C, et al. (2008) Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 153: 886-893.
32. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, et al. (2005) Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 68: 226-232.
33. Vicari E, La Vignera S, Condorelli R, Calogero AE, (2010) Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. J Sex Med 7: 1247-1253.